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Abstract
Objective—To estimate the optimal screen-positive 1-hour 50 gm glucose challenge test (GCT) 
threshold for gestational diabetes (GDM) and predictive characteristics of increasing screen-
positive GCT threshold values (135-199 mg/dL) for GDM.
Study Design—Secondary analysis of a multicenter mild GDM study. At 24-30 weeks' 
gestation, women with elevated GCT (135-199 mg/dL) completed a diagnostic 3-hour oral glucose 
tolerance test (OGTT). A novel change-point analysis method was used to compare the GDM rates 
for adjacent GCT values, delineating categories of changing risk such that values within categories 
have equal risk for GDM. Positive (PPV) and negative (NPV) predictive values for GDM were 
computed for increasing GCT cut-offs.
Results—In 7280 women with both GCT (135-199 mg/dL) and OGTT results, 4 GDM risk-
equivalent GCT categories were identified with escalations at 144, 158, and 174 mg/dL (all p-
values <0.05). The PPV for GDM increased from 33% to 64% as GCT increased from 135 to 199 
mg/dL while the NPV decreased from 80% to 67%. PPVs were only 20% and 61% for risk-
equivalent categories of 135-143 and 174-199 mg/dL respectively.
Conclusion—Elevated GCT cut-off values between 135-143 mg/dL may carry equivalent GDM 
risk. No threshold GCT value <199 mg/dL alone sufficiently predicts GDM.
Keywords
gestational diabetes mellitus; glucose challenge test; prediction; screening
Introduction
Gestational diabetes mellitus (GDM) complicates as many as 14% of pregnancies in the 
United States and is associated with adverse maternal and perinatal outcomes.1-5 There is 
currently a lack of consensus regarding the optimal approaches to screen and diagnose 
GDM.6,7 There is a lack of agreement on the use of a one or two step diagnostic approach. 
The American Diabetes Association (ADA) with the International Association of Diabetes 
and Pregnancy Study Groups (IADPSG) adopted the use of the single step 75 gm 2-hour 
OGTT approach.8,9 However, in the U.S. the two step approach is still most commonly used 
in accordance with findings from the 2013 NIH consensus conference and subsequent 
ACOG Bulletin on GDM. 4,10-11 In addition, for the two-step diagnostic strategy, the 
glucose level after a 1 hr 50-gram glucose challenge test (GCT) that is best to identify 
women at risk for GDM is controversial. 11-13 Positive screen cut-off values of 130, 135 or 
140 mg/dL are variably used; 140 mg/dL is reported to detect 80% of women who will be 
diagnosed with GDM based on the 3 hour oral glucose tolerance test (OGTT), while a value 
of 130 mg/dL identifies 90%.2 The American College of Obstetricians and Gynecologists 
recommends a 1 hour 50-gram screen-positive cut-off value of either 130 or 140 mg/dL.11 A 
value of 216 mg/dL or greater has been associated with100% positive predictive value (PPV) 
for GDM while a value of 200 mg/dL or greater (for which a diagnostic OGTT is often 
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bypassed) has a PPV >90%.2,14 These data are from relatively old studies and contradict 
studies suggesting 100% PPV at GCT thresholds below 200 mg/dl.
Given the lack of consensus concerning optimal cut-offs, relating more contemporary 
screening GCT results to OGTT results diagnostic of GDM may estimate new screening 
values for which diagnostic testing may be omitted and an optimal threshold for a positive 
screen result. The purpose of this study was to evaluate abnormal GCT results 135-199 
mg/dL as a screening test for the diagnosis of GDM using data collected in a GDM 
treatment trial.5 Specifically, we sought to estimate the optimal screen positive threshold for 
GDM and whether any abnormal GCT threshold values < 200 mg/dL afford sufficient PPV 
(i.e.,>90%) to diagnose GDM.
Materials and Methods
We conducted a secondary analysis of data collected from women enrolled as part of the 
multicenter GDM treatment trial supported by the Eunice Kennedy Shriver National Institute 
of Child Health and Human Development Maternal-Fetal Medicine Units network from 
October 2002 through November 2007.5 In the primary study, women with no history of 
diabetes whose blood glucose concentration at their local center was between 135-199 
mg/dL one hour after a 50 gm GCT at 24-30 weeks' gestation were invited to participate. 
Other exclusion criteria were abnormal glucose screening test prior to 24 weeks, prior 
gestational diabetes, prior stillbirth, multifetal pregnancy, asthma, chronic hypertension, 
corticosteroid therapy, known fetal anomaly and imminent preterm delivery. Eligible women 
completed a 3-hour OGTT that was analyzed centrally with clinicians blinded to the results. 
For this secondary analysis we included all women who had paired elevated GCT 
(135-199mg/dL) and OGTT results. GDM was defined by the Fourth International 
Workshop-Conference on Gestational Diabetes criteria as ≥ 2 abnormal OGTT values: 
fasting ≥95; 1-hr ≥180; 2-hr ≥155; 3-hr ≥140 mg/dL.2
Categorical variables were analyzed using the chi square test or Fisher's exact test. 
Continuous variables were analyzed using the Wilcoxon rank sum test or the Kruskal-Wallis 
test. Change-point analysis methodology with Bonferonni adjustment for multiple 
comparisons (p-value < 1.1×10-6) was used to partition abnormal GCT values into risk-
equivalent categories for GDM.15 Across the range from 135-199 mg/dL, the risks of GDM 
associated with adjacent GCT values were computed and compared. In this way, adjacent 
GCT values that showed statistically insignificant differences in GDM risk were used to 
delineate risk-equivalent GCT values. A modified dynamic programming algorithm was 
performed in order to achieve a global optimization for the partition of GCT range. More 
computational and statistical details have been described recently. 15 This is a novel 
application of change-point analysis methods. Unadjusted and adjusted odds ratios (OR) 
were calculated for risk-equivalent categories. The OR was adjusted for maternal age, body 
mass index (BMI) at enrollment and race/ethnicity. Positive predictive values (PPV), defined 
as the proportion of true positive among declared positives, and negative predictive values 
(NPV), defined as the proportion of true negative among declared negatives, were also 
computed for increasing GCT cut-offs along the range of 135-199 mg/dL. A result was 
considered statistically significant if the P-value was less than 0.05 and Bonferonni 
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adjustments were made for multiple comparisons. For supplementary analyses to evaluate 
whether results differed for Hispanic and non-Hispanic subgroups, likelihood ratio test was 
used. Analyses were performed with SAS statistical software (SAS Institute Inc, Cary NC) 
and R (http://www.r-project.org/). The primary study was approved by the Institutional 
Review Board at each participating center.
Results
Out of 7298 women who had OGTT (including the 958 diagnosed with mild GDM and 
randomized5), a total of 7280 women with paired elevated GCT (135-199 mg/dL) and 
OGTT results screened for the GDM trial constituted our study population. Their baseline 
characteristics are presented in Table 1. The majority of patients were of Hispanic ethnicity 
(51.5%); 20.9% were Black and 24.7% non-Hispanic White. The mean age was 27.4 years 
and mean BMI was 30.7. Mean abnormal GCT result was 154.8 mg/dL. These 
characteristics differed significantly between patients with and without GDM.
The risk of GDM based on the change-point analysis method is presented in Figure 1. 
Altogether, 4 different GDM risk-equivalent categories, corresponding to risk escalation at 
GCT values of 144, 158, and 174 mg/dL, were identified (p<0.05, Bonferroni adjusted). The 
risk of GDM was 20%, 28%, 42% and 61% for GCT values within risk equivalent categories 
of 135-143, 144-157, 158-173 and 174-199 mg/dL respectively. In Table 2, the unadjusted 
and adjusted OR (95% CI) for GDM associated with each risk-equivalent category of GCT 
relative to the first category (135-143 mg/dL) are given. There is a 1.6 to 6-fold increase in 
the risk of GDM with increasing GDM risk-equivalent category. The PPV and NPV (and 
their 95% CI) for escalating screen-positive cut-offs from 135-199 mg/dL are shown in 
Figure 2. The respective PPV and NPV values range from 35% and 80% for GCT value of 
140 to 63% and 67% for GCT of 195 mg/dL. If we used a GCT cut-off of 144 as screen 
positive among the 7280 patients with GCT 135-199, 1957 (26.9%) with GCT<144 would 
avoid a GTT. Of 2421 patients with GDM, 389 (16.1%) with GCT<144 will not be 
diagnosed with GDM.
In additional analyses, we evaluated whether our reported risk-equivalent GCT categories 
differed by Hispanic or non-Hispanic subgroups. We compared findings for each subgroup 
to the reported overall risk-equivalent GCT categories. Our findings in the Hispanic 
subgroup (p= 0.168) and the non-Hispanic subgroup (p= 0.149) did not differ significantly 
from the overall findings. We also evaluated whether the risk-equivalent GCT categories 
differed by obesity status (BMI ≥30 at enrollment vs. BMI<30 at enrollment). We compared 
findings for each subgroup to the reported overall risk-equivalent GCT categories. Our 
findings in the obese subgroup (p=0.059) and the non-obese subgroup (p=0.693) did not 
differ significantly from the overall findings.
Comment
Based on a novel application of change-point analysis method, we identified 4 risk-
equivalent categories along the range of abnormal GCT values from 135-199 mg/dL. These 
risk-equivalent GLT categories applied equally to both Hispanic and non-Hispanic 
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subgroups. The risk or PPV for GDM increased from 20% for GCT category 135-143 
mg/dL to 61% for GCT category 174-199 mg/dL. In addition, the PPVs corresponding to 5-
unit increments of abnormal GCT values from 135- 195 mg/dL ranged from 33 to 64% only. 
Therefore, no cut-off abnormal GCT value <199 mg/dL alone appeared sufficient (PPV 
>90%) for the diagnosis of GDM without an OGTT. The equivalence in GDM risk of GCT 
values between 135 and 143 mg/dL based on the novel method suggests that a screen 
positive cut-off as high as 144 rather than the empirical 140 (based on a 5 unit difference 
alone) should be evaluated as an alternative to 135 mg/dL. At the cut-off of 144, 26.9% of 
women who currently undergo GTT testing would not need to have the test, and the 
prevalence of 16.1% of women with a diagnosis of GDM would avoid the diagnosis.
In one study a GCT screen-positive cut-off of 143 mg/dL yielded a sensitivity of 83% and 
specificity of 87% while a cut-off of 135 mg/dL yielded a sensitivity of 100% and a 
specificity of 80%. Similar to our study, the probability of GDM for escalating screen-
positive cut-offs ranged from 15% in the 135-144 mg/dL group to 50% in the 175-184 
mg/dL group. However the probability of GDM was 100% when the GCT was greater than 
185 mg/dL a finding that we do not replicate. There were no women diagnosed with GDM 
in the GCT range of 130-134 mg/dL.16 One study suggested that variation in screen positive 
thresholds for the GCT based on a woman's risk score for GDM (determined by age, BMI 
and race) would reduce the number of screening tests and increase the GDM detection 
rate.17 However this approach is not in common use in the US. Our data from a large 
contemporary cohort suggests that GCT values <144mg/dL confer GDM risk equivalent to 
risk associated with a GCT of 135.
Our study has a number of limitations. We did not include patients with GCT results <135 or 
≥ 200 mg/dL. This did not allow for an evaluation of continuous GCT in these ranges and 
limited the calculation of PPV and NPV applicable to the entire screened population. Also, 
we could not compare our findings to those for the common alternative GCT cut-off of 130 
mg/dL for a screen positive cut-off used by some providers. Our findings using a novel 
statistical application warrant further validation in a larger population. Of note, the study 
population did not include patients with prior history of gestational diabetes or chronic 
hypertension, limiting the generalizability to these patients and non-US cohorts with a 
different racial-ethnic make-up and less obesity.
The strengths of our study include the large number of contemporaneous women with 
elevation of GCT and the use of novel change-point analysis methodology to predict GDM. 
Thus these findings are directly applicable to patients with elevated GCT.
There is currently a lack of consensus worldwide regarding whether the one step (2-hour 75 
gm OGTT) vs. a two-step (typically a 1-hour 50 gm GCT and 3-hour 100 gm OGTT) 
strategy for the diagnosis of GDM should be used.13 The American College of Obstetricians 
and Gynecologists (ACOG) recommends that all pregnant women be screened according to 
their history, clinical risk factors, or a laboratory screening test, and that laboratory screening 
and diagnosis may be omitted for low risk women. 11 Further, ACOG recommends the two 
step approach for those at high risk for GDM. 10,11 There appears to be poor agreement 
between the two tests and more women are diagnosed with GDM based on the 3-hour 
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OGTT (12% vs. 5% in one study).18 However, the screen positive rates will vary depending 
on the threshold value used for the 1-hour GCT and 3-hour GTT. On the strength of large 
clinical trials and observational studies the OGTT cut-offs based on the 4th International 
Workshop-Conference are commonly used.2,5,19 Several studies including a randomized trial 
also suggest that the two step approach involves less cost. 20-22
Overall, our results suggest that given the changes in GDM risk, cut-offs different from the 
traditional 5-unit increments should be considered for further evaluation of the GCT. Thus, 
144 mg/dL instead of 140 may be evaluated as an alternative to 135 mg/dL, for 
recommending an OGTT. Furthermore, no single abnormal value <200 mg/dL appears 
sufficient (without an OGTT) for the diagnosis of GDM. Given the relative linear 
association between levels of glycemia and adverse pregnancy outcomes, impact on 
pregnancy outcomes is also an important dimension to be considered in setting screen-
positive thresholds.4,23 Data from a separate analysis of a sample of our study cohort with 
pregnancy outcomes suggest that GCT values of 140 or greater but not 135-139 mg/dL are 
associated with adverse pregnancy outcomes.24 Therefore, considered together, GCT screen-
positive cut-offs higher than 135 mg/dL, and as high as 143 mg/dL appear to be appropriate.
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Figure 1. Risk Equivalent Categories for the Probability of GDM Versus GCT Value
A change-point analysis method compared the outcome rates of GDM for adjacent GCT 
values. It identified 4 stepwise categories of increasing outcome rate for GDM. The values 
within each category carry a statistically equivalent risk for GDM. The black horizontal lines 
represent these 4 identified categories. The gray dots represent point-wise estimated 
probabilities of GDM for GCT values.
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Figure 2. The PPV and NPV for escalating GCT screen-positive cut-offs from 135-199 mg/dl
The 95% CI are also depicted around the PPV and NPV values.
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Table 1
Characteristics of the study population
All
N=7280
GDM
N=2421
No GDM
N=4859
P-value
Age-yr* 27.4 ±5.7 28.9±5.8 26.7±5.6 <0.001
Race or ethnic group-no. (%)
 Black 1523 (20.9%) 367 (15.2%) 1156 (23.8%) <0.001
 White 1797 (24.7%) 522 (21.6%) 1275 (26.2%)
 Hispanic 3751 (51.5%) 1422 (58.7%) 2329 (47.9%)
 Other 209 (2.9%) 110 (4.5%) 99 (2.0%)
Glucose level after 50-g GCT –mg/dL* 154.8±14.7 160.5±16.0 151.9±13.0 <0.001
BMI at enrollment* 30.7±6.1 32.4±6.3 29.9±5.9 <0.001
*
The values are mean +/- SD
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Table 2
Odds ratios for mild GDM by escalating GCT category with 135-143 mg/dL as the 
referent
GCT Category Unadjusted OR (95% CI) Adjusted OR (95% CI)*
135-143 mg/dL
(n=1957)
Referent Referent
144-157 mg/dL
(n=2729)
1.59 (1.38-1.82) 1.50 (1.29-1.74)
158-173 mg/dL
(n=1676)
2.91 (2.51-3.38) 2.82 (2.41-3.31)
174-199 mg/dL
(n=918)
6.25 (5.26-7.43) 5.79 (4.79-6.99)
*Adjusted for maternal age, BMI at enrollment and ethnicity
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